AngioDynamics, Inc. filings document regulatory disclosures for a Nasdaq-listed medical technology company focused on vascular disease, thrombectomy, oncology and surgical device markets. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD investor presentation materials, and forward-looking statement language tied to product strategy, competitive position, cash flows and operating plans.
The filing record also covers governance and material-event disclosures, including annual meeting voting results, director elections, auditor ratification, advisory executive-compensation votes, executive transition and retirement arrangements, and patent-enforcement litigation involving the company’s thrombectomy intellectual property and self-expanding funnel technology. Proxy materials provide compensation tables, board matters and shareholder-vote mechanics.
AngioDynamics Inc. executive Chad Thomas Campbell, SVP/GM Vascular Access, reported tax-related dispositions totaling 3,838 shares of common stock. On July 16, 17, and 20, 2026, shares were withheld at $14.14, $13.51, and $13.71 per share to satisfy tax withholding obligations from pre-determined vesting of restricted stock units granted in 2025, 2024, and 2022.
AngioDynamics, Inc. reports on its medical technology business designing, manufacturing and selling devices used to treat cardiovascular disease and cancer. Products are organized into Med Tech (Auryon atherectomy, AlphaVac and AngioVac thrombectomy systems, NanoKnife IRE ablation, Solero microwave ablation) and Med Device lines.
The company has reshaped its portfolio by selling dialysis, BioSentry, PICC and Midline businesses and discontinuing RadioFrequency Ablation and Syntrax, while planning a shift of additional manufacturing to third-party partners, including Costa Rica, by the first quarter of fiscal 2027. NanoKnife received expanded FDA 510(k) clearance for prostate ablation and MDR CE mark approval covering pancreas, kidney, liver and prostate tumors.
AngioDynamics lists intense competition from large device makers, pricing pressure from group purchasing organizations, dependence on key suppliers and international distributors, complex global regulation and potential product-liability and compliance exposure as principal risks. It employed 632 people as of May 31, 2026, and its CEO has announced plans to retire by late 2026.
AngioDynamics reported record fiscal 2026 results, with pro forma net sales of $320.2 million, up 9.4% from a year earlier, and fourth‑quarter net sales of $86.6 million, up 8.0%. Med Tech revenue grew 18.4% to $150.0 million, while Med Device revenue rose 2.5% to $170.2 million, lifting gross margin to 54.6%.
Despite stronger sales, the company posted a GAAP net loss of $36.7 million, or $0.88 per share, though adjusted net loss was $10.0 million and adjusted EBITDA increased to $13.2 million from $7.6 million. Cash from operations was $3.1 million for the year, and AngioDynamics ended May 31, 2026 with $53.9 million in cash and a debt‑free balance sheet.
Growth was led by the Auryon atherectomy system, Mechanical Thrombectomy portfolio and NanoKnife platform, which benefited from new clinical data, FDA IDE approvals and improved reimbursement including Category I CPT codes and a Medicare local coverage determination. For fiscal 2027, the company guides net sales to $336–$341, Med Tech growth of 12–15%, gross margin of 54–55%, and adjusted EBITDA of $13–$16.
AngioDynamics, Inc. Schedule 13G/A: Point72 reports beneficial ownership of 3,181,829 shares of common stock, representing 7.7% of the class as of March 31, 2026. The shares are held by Point72 Associates; voting and dispositive power are reported as shared. Point72 Asset Management and Point72 Capital Advisors Inc. state they own no shares directly; Steven A. Cohen is reported to control the filing entities.
AngioDynamics reported higher sales but remained unprofitable for the quarter ended February 28, 2026. Revenue rose 8.9% to $78.4 million, driven by 19.0% growth in Med Tech and 1.2% growth in Med Device.
Quarterly gross margin slipped to 52.9% as tariffs, inflation and Med Device mix offset volume and outsourcing benefits. Net loss widened to $8.1 million (loss per share $0.19) from $4.4 million, largely reflecting higher restructuring and CEO transition costs.
For the nine months, revenue increased to $233.6 million (up 10.0%) and net loss improved to $25.3 million (loss per share $0.61) from $27.9 million. The company ended the period with $37.8 million in cash, no debt and access to a $25.0 million revolving credit facility while continuing a multi‑year manufacturing footprint restructuring and ongoing payments under a patent settlement with BD.
AngioDynamics reported fiscal Q3 2026 results showing solid Med Tech–led growth but continued GAAP losses. Net sales were $78.4 million, up 8.9% year over year, with Med Tech revenue of $37.3 million growing 19.0% and Med Device revenue of $41.1 million up 1.1%.
Gross margin was 52.9%, down 110 basis points, reflecting tariffs, inflation and manufacturing transition costs. The company posted a GAAP net loss of $8.1 million, or ($0.19) per share, and a pro forma adjusted net loss of $3.0 million, or ($0.07) per share, while pro forma adjusted EBITDA improved to $1.8 million.
AngioDynamics ended the quarter with $37.8 million in cash and no debt. It raised full-year 2026 guidance, now expecting net sales of $313.5–$315.5 million, Med Tech growth of 15–17%, adjusted EBITDA of $10.0–$12.0 million, and adjusted EPS between ($0.30) and ($0.23).
AngioDynamics Inc amendment shows The Vanguard Group reports 0 shares of Common Stock beneficially owned, representing 0% of the class as stated in the filing. The amendment explains an internal realignment effective January 12, 2026, leading Vanguard and certain subsidiaries to report holdings separately.
AngioDynamics, Inc. received an amended Schedule 13G/A from Divisadero Street Capital Management and related entities, along with William Zolezzi, reporting a very small passive position in its common stock. The group reports beneficial ownership of 4,576 shares, representing 0.01% of AngioDynamics’ outstanding common stock.
The filing shows no sole voting or dispositive power over the shares; all reported power is shared among the reporting persons. All of the securities are directly owned by advisory clients of Divisadero Street Capital Management, and each reporting person disclaims beneficial ownership beyond any pecuniary interest.
The group certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of AngioDynamics, and that overall ownership remains at or below 5% of the class.
Systematic Financial Management filed a Schedule 13G reporting a passive ownership stake in AngioDynamics Inc. common stock. The firm beneficially owns 2,508,295 shares, representing 6.05% of the outstanding common stock, with sole voting power over 1,478,345 shares and sole dispositive power over all 2,508,295 shares.
The filing states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of AngioDynamics. The reported holdings relate to AngioDynamics common stock with CUSIP 03475V101.